Bokf, Na Sage Therapeutics, Inc. Transaction History

Bokf, Na

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$27.52 - $37.99 $3,687 - $5,090	-134 Reduced 0.79%	16,933 $547,000
Q1 2022 May 13, 2022	BUY	$30.71 - $45.71 $39,462 - $58,737	1,285 Added 8.14%	17,067 $565,000
Q4 2021 Mar 11, 2022	SELL	$37.06 - $47.11 $53,996 - $68,639	-1,457 Reduced 8.45%	15,782 $671,000
Q3 2021 Nov 10, 2021	BUY	$40.26 - $57.37 $694,042 - $989,001	17,239 New	17,239 $764,000
Q1 2020 May 13, 2020	SELL	$26.15 - $77.24 $268,900 - $794,258	-10,283 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$60.18 - $154.77 $618,830 - $1.59 Million	10,283 New	10,283 $742,000
Q3 2019 Nov 13, 2019	SELL	$140.29 - $189.96 $156,002 - $211,235	-1,112 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$157.85 - $183.09 $175,529 - $203,596	1,112 New	1,112 $203,000

218

48.2M

854K

195K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $395M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Bokf, Na, based on Form 13F filings with the SEC.

Stay updated on Bokf, Na with notifications on news.